Restless legs syndrome refers to the strong urge to move legs. It can also cause unpleasant crawling or peristaltic sensations in the feet, calves, and thighs. The feeling is usually worse at evening or at night times. Restless legs syndrome is also related to involuntary moving of the legs and arms, called periodic limb movement during sleep (PLMS). There is no exact cause of this syndrome but iron deficiency anemia, kidney failure, last three months of pregnant women, and idiopathic can be the cause of this syndrome. Adoption of good sleeping habits, quitting smoking, and regular exercise are recommended with medication.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the global restless legs syndrome market.
Top Impacting Factors
- Rise in prevalence of restless legs syndrome, increase in consumption of alcohol & tobacco, surge in peoples suffering from stress & psychotic problems, rise in peoples suffer from hypersensitivity, and surge in sleep apnea cases are the key factors that drive the growth of the market.
- In addition, surge in adoption of highly advance therapy devices, huge financial support from government & private funding for healthcare sector development, high demand of disease specific novel treatment, ongoing research for rare disease treatment by R & D activities, collaboration & mergers between local & key market players, and rise in genetic heredity disorders are expected to drive the growth of the market.
- However, ignorance related treatment of restless syndrome and lack of effective treatment hinder the growth of the market.
- Contrarily, growth opportunities in emerging markets is expected to offer lucrative opportunities for the expansion of the market.
Market Trends
R&D Activities for Launch of Novel Products
In 2021, new observational study by the non-profit research institute RTI International found that individuals have a significantly higher likelihood of developing restless legs syndrome (RLS) when consuming medications commonly used to reduce acid reflux
In 2019, Serina Therapeutics developed rotigotine, officially known as SER-214, a dopamine agonist for the treatment of restless legs syndrome (RLS). If the trial is successful, it will significantly change the treatment pattern of patients and doctors around the world.
Key Benefits of the Report
- This study presents the analytical depiction of global restless legs syndrome market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Global Restless Legs Syndrome Market Report
- Which are the leading players active in the global restless legs syndrome market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "global restless legs syndrome"?
- What is "global restless legs syndrome" market prediction in the future?
- Who are the leading global players in the "global restless legs syndrome" market?
- What are the current trends and predicted trends?
- What are the key benefits of the "global restless legs syndrome" market report?
Restless Leg Syndrome Market, by Type Report Highlights
| Aspects | Details |
 By Type |
|
 By Drugs |
|
 By Route of Administration |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Mylan N.V., Serina Therapeutics, Aurobindo Pharma, Novartis AG, Endo Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd, Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd, Macleods Pharmaceuticals Ltd., Apotex Inc, Dr. Reddy’s Laboratories Ltd, Alembic Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd, Zydus Cadila |
Loading Table Of Content...
